Skip to Main Content
DownloadHi-Res Photo

Michael Girardi, MD, FAAD

Evans Professor of Dermatology; Director, Residency Program, Dermatology; Vice Chair, Dermatology; Co-Director, T32 Research Fellowship Program, Dermatology

Contact Information

Michael Girardi, MD, FAAD

Mailing Address

  • Dermatology

    PO Box 208059, 333 Cedar Street

    New Haven, CT 06520-8059

    United States

Girardi Lab

Related Links

Yale Medicine

Patient Care

Are you a patient?Please visit the Yale Medicine website for information about the services we offer and making an appointment.View Doctor Profile

Research Summary

Dr. Girardi’s principal research focus as a faculty member has been to investigate the relationship between the immune system and cancer from two complimentary perspectives: as a laboratory / translational investigator, and as a clinical scholar. He has published in high impact journals (Science, Nature, New England Journal, Nature Immunology, Journal of Experimental Medicine, Proceedings of the National Academy of Sciences). In addition, he has developed an internationally recognized clinical expertise in several areas including cutaneous T cell lymphoma (CTCL), squamous cell carcinoma (SCC), and the immunodulatory treatment extracorporeal photochemotherapy (ECP). His scientific and clinical scholarly accomplishments have been recently recognized by his elected membership into the American Society for Clinical Investigation. His laboratory has made several advances in our understanding of the immunoregulation of carcinogenesis.

Specialized Terms: Cancer; Carcinogenesis; Cellular Immunology; Chemotherapy; Dermatology; DNA; Immunobiology; Immunology; Lymphoma; Receptors; Tumor Immunology

Extensive Research Description

Dr. Girardi’s current research projects include:

(1) The role of local immune cells in the development of cutaneous carcinogenesis. The Girardi laboratory is dissecting how various immune cells, resident within and recruited to the skin, contribute the skin cancer development. Previously, the Girardi lab elucidated a critical, entirely unforeseen, role for Langerhans cells (LC) in cutaneous carcinogenesis and established a paradigm for resident dendritic cell influences on mutagenesis within epithelial tissues more generally, while definitively demonstrating that LC exert major influences in both stimulating keratinocyte mutagenesis as well as facilitating tumor promotion. More recently, Dr. Girardi revealed a major and again unanticipated influence for LC in UVB-induced p53 mutant keratinocyte clonal expansion.

(2) Novel approaches to the diagnosis and treatment of cutaneous T cell lymphoma (CTCL). Currently funded by the Spatz Foundation, the Girardi lab focuses on the identification of genetic drivers of cutaneous T cell lymphoma (CTCL) and therapeutic innovation for the personalized treatment of CTCL. Dr. Girardi is utilizing innovative techniques in CTCL cell isolation and nanoscale acoustic-transfer automated drug screening to screen and identify novel agents effective against CTCL. Previouisly, the Girardi lab had provided the most comprehensive description of gene copy number alterations in CTCL. More recently, in collaboration with R. Lifton (Yale Genetics), these investigators fully elucidate the genetic drivers of CTCL. Dr. Girardi continues to be engaged in studies to characterize several therapeutic approaches to CTCL, including research into mechanisms underlying extracorporeal photopheresis.

(3) Biodegradable nanotechnology in the prevention and treatment of skin cancer. In collaboration with W.M. Saltzman, and funded by the Yale SPORE in Skin Cancer and the Yale Blavatnik Fund for Innovation, Dr. Girardi has developed a translational sub-program of nanoparticle-based prevention of keratinocyte mutagenesis and the tumor-promoting effects of chemical and UVB exposure. This directly led to the development of a novel sunscreen characterized by superior safety and efficacy, and will form the basis for continued translational studies. In collaboration with Saltzman and D. Brash, the Dr. Girardi is investigating novel approaches to melanoma prevention using nanoparticles to limit direct and indirect effects of UV-induced DNA damage after sun exposure.

Coauthors

Research Interests

Dermatology; DNA; Graft vs Host Disease; Immune System; Internship and Residency; Skin Neoplasms; Lymphoma, T-Cell, Cutaneous; Carcinogenesis

Research Images

Selected Publications

  • Real-world experience with mechlorethamine gel in patients with mycosis fungoides-cutaneous lymphoma: Preliminary findings from a prospective observational study.Kim EJ, Geskin L, Guitart J, Querfeld C, Girardi M, Musiek A, Mink DR, Williams MJ, Angello JT, Bailey WL. Real-world experience with mechlorethamine gel in patients with mycosis fungoides-cutaneous lymphoma: Preliminary findings from a prospective observational study. Journal Of The American Academy Of Dermatology 2020, 83: 928-930. PMID: 32089294, DOI: 10.1016/j.jaad.2019.12.070.
  • Low-Dose Intralesional Recombinant Interferon-α2b in the Treatment of Mycosis Fungoides.Hu JK, Carlson K, Girardi M. Low-Dose Intralesional Recombinant Interferon-α2b in the Treatment of Mycosis Fungoides. The Yale Journal Of Biology And Medicine 2020, 93: 41-44. PMID: 32226334, PMCID: PMC7087069.
  • Cutaneous Photoprotection: A Review of the Current Status and Evolving Strategies.Suozzi K, Turban J, Girardi M. Cutaneous Photoprotection: A Review of the Current Status and Evolving Strategies. The Yale Journal Of Biology And Medicine 2020, 93: 55-67. PMID: 32226337, PMCID: PMC7087054.
  • Insights Into the Molecular and Cellular Underpinnings of Cutaneous T Cell Lymphoma.Yumeen S, Girardi M. Insights Into the Molecular and Cellular Underpinnings of Cutaneous T Cell Lymphoma. The Yale Journal Of Biology And Medicine 2020, 93: 111-121. PMID: 32226341, PMCID: PMC7087059.
  • United States Cutaneous Lymphoma Consortium recommendations for treatment of cutaneous lymphomas during the COVID-19 pandemic.Zic JA, Ai W, Akilov OE, Carter JB, Duvic M, Foss F, Girardi M, Gru AA, Kim E, Musiek A, Olsen EA, Schieke SM, Shinohara M, Zain JM, Geskin LJ. United States Cutaneous Lymphoma Consortium recommendations for treatment of cutaneous lymphomas during the COVID-19 pandemic. Journal Of The American Academy Of Dermatology 2020, 83: 703-704. PMID: 32305443, PMCID: PMC7161526, DOI: 10.1016/j.jaad.2020.04.049.
  • CD8+ mycosis fungoides palmaris et plantaris with peripheral blood involvement.Yumeen S, Mirza FN, Lewis JM, Carlson KR, King B, Cowper S, Bunick CG, McNiff J, Girardi M. CD8+ mycosis fungoides palmaris et plantaris with peripheral blood involvement. JAAD Case Reports 2020, 6: 434-437. PMID: 32382639, PMCID: PMC7200192, DOI: 10.1016/j.jdcr.2020.02.025.
  • JAK inhibition synergistically potentiates BCL2, BET, HDAC, and proteasome inhibition in advanced CTCL.Yumeen S, Mirza FN, Lewis JM, King ALO, Kim SR, Carlson KR, Umlauf SR, Surovtseva YV, Foss FM, Girardi M. JAK inhibition synergistically potentiates BCL2, BET, HDAC, and proteasome inhibition in advanced CTCL. Blood Advances 2020, 4: 2213-2226. PMID: 32437546, PMCID: PMC7252559, DOI: 10.1182/bloodadvances.2020001756.
  • Screening Novel Agent Combinations to Expedite CTCL Therapeutic Development.Mirza FN, Yumeen S, Lewis JM, King ALO, Kim SR, Carlson KR, Umlauf S, Surovtseva YV, Foss FM, Girardi M. Screening Novel Agent Combinations to Expedite CTCL Therapeutic Development. The Journal Of Investigative Dermatology 2021, 141: 217-221. PMID: 32534802, DOI: 10.1016/j.jid.2020.05.097.
  • Clarification Regarding Noninferiority and a Discussion of Model Selection and Treatment Effects in Observational Research-Reply.Cheraghlou S, Agogo GO, Girardi M. Clarification Regarding Noninferiority and a Discussion of Model Selection and Treatment Effects in Observational Research-Reply. JAMA Dermatology 2020, 156: 1029. PMID: 32520348, DOI: 10.1001/jamadermatol.2020.0543.
  • Outcomes for allogeneic stem cell transplantation in refractory mycosis fungoides and primary cutaneous gamma Delta T cell lymphomas.Isufi I, Seropian S, Gowda L, Wilson LD, Roberts K, Girardi M, Perreault S, Foss F. Outcomes for allogeneic stem cell transplantation in refractory mycosis fungoides and primary cutaneous gamma Delta T cell lymphomas. Leukemia & Lymphoma 2020, 61: 2955-2961. PMID: 32643494, DOI: 10.1080/10428194.2020.1790555.
  • Disease site as a prognostic factor for mycosis fungoides: an analysis of 2428 cases from the US National Cancer Database.Su C, Tang R, Bai HX, Girardi M, Karakousis G, Zhang PJ, Xiao R, Zhang G. Disease site as a prognostic factor for mycosis fungoides: an analysis of 2428 cases from the US National Cancer Database. British Journal Of Haematology 2019, 185: 592-595. PMID: 30216417, DOI: 10.1111/bjh.15570.
  • Treatment of primary nonmetastatic melanoma at high-volume academic facilities is associated with improved long-term patient survival.Cheraghlou S, Agogo GO, Girardi M. Treatment of primary nonmetastatic melanoma at high-volume academic facilities is associated with improved long-term patient survival. Journal Of The American Academy Of Dermatology 2019, 80: 979-989. PMID: 30365997, DOI: 10.1016/j.jaad.2018.10.026.
  • Biodegradable bioadhesive nanoparticle incorporation of broad-spectrum organic sunscreen agents.Suh HW, Lewis J, Fong L, Ramseier JY, Carlson K, Peng ZH, Yin ES, Saltzman WM, Girardi M. Biodegradable bioadhesive nanoparticle incorporation of broad-spectrum organic sunscreen agents. Bioengineering & Translational Medicine 2019, 4: 129-140. PMID: 30680324, PMCID: PMC6336670, DOI: 10.1002/btm2.10092.
  • Evaluation of Lymph Node Ratio Association With Long-term Patient Survival After Surgery for Node-Positive Merkel Cell Carcinoma.Cheraghlou S, Agogo GO, Girardi M. Evaluation of Lymph Node Ratio Association With Long-term Patient Survival After Surgery for Node-Positive Merkel Cell Carcinoma. JAMA Dermatology 2019, 155: 803-811. PMID: 30825411, PMCID: PMC6583886, DOI: 10.1001/jamadermatol.2019.0267.
  • System-level variations in treatment delay for nonmetastatic melanoma.Cheraghlou S, Agogo GO, Girardi M. System-level variations in treatment delay for nonmetastatic melanoma. Journal Of The American Academy Of Dermatology 2019, 81: 1399-1401. PMID: 31009671, DOI: 10.1016/j.jaad.2019.04.038.
  • Effect of leucovorin administration on mucositis and skin reactions in patients with peripheral T-cell lymphoma or cutaneous T-cell lymphoma treated with pralatrexate.Foss FM, Parker TL, Girardi M, Li A. Effect of leucovorin administration on mucositis and skin reactions in patients with peripheral T-cell lymphoma or cutaneous T-cell lymphoma treated with pralatrexate. Leukemia & Lymphoma 2019, 60: 2927-2930. PMID: 31119966, DOI: 10.1080/10428194.2019.1612061.
  • Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells.Ventura A, Vassall A, Yurter A, Robinson E, Filler R, Hanlon D, Meeth K, Ezaldein H, Girardi M, Sobolev O, Bosenberg MW, Edelson RL. Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells. Journal Of Visualized Experiments : JoVE 2019 PMID: 31157760, DOI: 10.3791/59370.
  • The impact of facility characteristics on Merkel cell carcinoma outcomes: a retrospective cohort study.Cheraghlou S, Agogo GO, Girardi M. The impact of facility characteristics on Merkel cell carcinoma outcomes: a retrospective cohort study. Journal Of The American Academy Of Dermatology 2019 PMID: 31473294, DOI: 10.1016/j.jaad.2019.08.058.
  • Comparison of Survival After Mohs Micrographic Surgery vs Wide Margin Excision for Early-Stage Invasive Melanoma.Cheraghlou S, Christensen SR, Agogo GO, Girardi M. Comparison of Survival After Mohs Micrographic Surgery vs Wide Margin Excision for Early-Stage Invasive Melanoma. JAMA Dermatology 2019, 155: 1252-1259. PMID: 31553403, PMCID: PMC6764120, DOI: 10.1001/jamadermatol.2019.2890.
  • Transplantation in the Treatment of Primary Cutaneous Aggressive Epidermotropic Cytotoxic CD8-Positive T-Cell Lymphoma.Cyrenne BM, Gibson JF, Subtil A, Girardi M, Isufi I, Seropian S, Foss F. Transplantation in the Treatment of Primary Cutaneous Aggressive Epidermotropic Cytotoxic CD8-Positive T-Cell Lymphoma. Clinical Lymphoma, Myeloma & Leukemia 2018, 18: e85-e93. PMID: 29223388, DOI: 10.1016/j.clml.2017.11.004.
  • Predicting non-melanoma skin cancer via a multi-parameterized artificial neural network.Roffman D, Hart G, Girardi M, Ko CJ, Deng J. Predicting non-melanoma skin cancer via a multi-parameterized artificial neural network. Scientific Reports 2018, 8: 1701. PMID: 29374196, PMCID: PMC5786038, DOI: 10.1038/s41598-018-19907-9.
  • Commensal orthologs of the human autoantigen Ro60 as triggers of autoimmunity in lupus.Greiling TM, Dehner C, Chen X, Hughes K, Iñiguez AJ, Boccitto M, Ruiz DZ, Renfroe SC, Vieira SM, Ruff WE, Sim S, Kriegel C, Glanternik J, Chen X, Girardi M, Degnan P, Costenbader KH, Goodman AL, Wolin SL, Kriegel MA. Commensal orthologs of the human autoantigen Ro60 as triggers of autoimmunity in lupus. Science Translational Medicine 2018, 10 PMID: 29593104, PMCID: PMC5918293, DOI: 10.1126/scitranslmed.aan2306.
  • Pillars Article: Regulation of Cutaneous Malignancy by γδ T Cells. Science. 2001. 294: 605-609.Girardi M, Oppenheim DE, Steele CR, Lewis JM, Glusac E, Filler R, Hobby P, Sutton B, Tigelaar RE, Hayday AC. Pillars Article: Regulation of Cutaneous Malignancy by γδ T Cells. Science. 2001. 294: 605-609. Journal Of Immunology (Baltimore, Md. : 1950) 2018, 200: 3031-3035. PMID: 29685949.
  • Extracorporeal Photochemotherapy Drives Monocyte-to-Dendritic Cell Maturation to Induce Anticancer Immunity.Ventura A, Vassall A, Robinson E, Filler R, Hanlon D, Meeth K, Ezaldein H, Girardi M, Sobolev O, Bosenberg MW, Edelson RL. Extracorporeal Photochemotherapy Drives Monocyte-to-Dendritic Cell Maturation to Induce Anticancer Immunity. Cancer Research 2018, 78: 4045-4058. PMID: 29764863, DOI: 10.1158/0008-5472.CAN-18-0171.
  • An Integrated Data Resource for Genomic Analysis of Cutaneous T-Cell Lymphoma.Chang LW, Patrone CC, Yang W, Rabionet R, Gallardo F, Espinet B, Sharma MK, Girardi M, Tensen CP, Vermeer M, Geskin LJ. An Integrated Data Resource for Genomic Analysis of Cutaneous T-Cell Lymphoma. The Journal Of Investigative Dermatology 2018, 138: 2681-2683. PMID: 29981755, DOI: 10.1016/j.jid.2018.06.176.
  • Treatment of generalized deep morphea and eosinophilic fasciitis with the Janus kinase inhibitor tofacitinib.Kim SR, Charos A, Damsky W, Heald P, Girardi M, King BA. Treatment of generalized deep morphea and eosinophilic fasciitis with the Janus kinase inhibitor tofacitinib. JAAD Case Reports 2018, 4: 443-445. PMID: 29984277, PMCID: PMC6031588, DOI: 10.1016/j.jdcr.2017.12.003.
  • BET inhibition in advanced cutaneous T cell lymphoma is synergistically potentiated by BCL2 inhibition or HDAC inhibition.Kim SR, Lewis JM, Cyrenne BM, Monico PF, Mirza FN, Carlson KR, Foss FM, Girardi M. BET inhibition in advanced cutaneous T cell lymphoma is synergistically potentiated by BCL2 inhibition or HDAC inhibition. Oncotarget 2018, 9: 29193-29207. PMID: 30018745, PMCID: PMC6044378, DOI: 10.18632/oncotarget.25670.
  • Clinical Activity of Pralatrexate in Patients With Cutaneous T-Cell Lymphoma Treated With Varying Doses of Pralatrexate.Foss FM, Parker TL, Girardi M, Li A. Clinical Activity of Pralatrexate in Patients With Cutaneous T-Cell Lymphoma Treated With Varying Doses of Pralatrexate. Clinical Lymphoma, Myeloma & Leukemia 2018, 18: e445-e447. PMID: 30181105, DOI: 10.1016/j.clml.2018.06.020.
  • Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients.Cyrenne BM, Lewis JM, Weed JG, Carlson KR, Mirza FN, Foss FM, Girardi M. Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients. Blood 2017, 130: 2073-2083. PMID: 28972015, PMCID: PMC5680613, DOI: 10.1182/blood-2017-06-792150.
  • FISH Panel for Leukemic CTCL.Weed J, Gibson J, Lewis J, Carlson K, Foss F, Choi J, Li P, Girardi M. FISH Panel for Leukemic CTCL. The Journal Of Investigative Dermatology 2017, 137: 751-753. PMID: 27836797, PMCID: PMC5419071, DOI: 10.1016/j.jid.2016.10.037.
  • Annual Facility Treatment Volume and Patient Survival for Mycosis Fungoides and Sézary Syndrome.Kann BH, Park HS, Yeboa DN, Aneja S, Girardi M, Foss FM, Roberts KB, Wilson LD. Annual Facility Treatment Volume and Patient Survival for Mycosis Fungoides and Sézary Syndrome. Clinical Lymphoma, Myeloma & Leukemia 2017, 17: 520-526.e2. PMID: 28655598, DOI: 10.1016/j.clml.2017.05.017.
  • Primary cutaneous aggressive epidermotropic cytotoxic CD8+ T-cell lymphoma: long-term remission after brentuximab vedotin.Cyrenne BM, Subtil A, Girardi M, Foss F. Primary cutaneous aggressive epidermotropic cytotoxic CD8+ T-cell lymphoma: long-term remission after brentuximab vedotin. International Journal Of Dermatology 2017, 56: 1448-1450. PMID: 29047111, DOI: 10.1111/ijd.13792.
  • Mycosis Fungoides and Sezary Syndrome.Foss FM, Girardi M. Mycosis Fungoides and Sezary Syndrome. Hematology/oncology Clinics Of North America 2017, 31: 297-315. PMID: 28340880, DOI: 10.1016/j.hoc.2016.11.008.
  • Primary cutaneous aggressive epidermotropic cytotoxic T-cell lymphomas: reappraisal of a provisional entity in the 2016 WHO classification of cutaneous lymphomas.Guitart J, Martinez-Escala ME, Subtil A, Duvic M, Pulitzer MP, Olsen EA, Kim E, Rook AH, Samimi SS, Wood GS, Girardi M, Junkins-Hopkins J, Ivan DS, Selim MA, Sable KA, Virmani P, Pincus LB, Tetzlaff MT, Kim J, Kim YH. Primary cutaneous aggressive epidermotropic cytotoxic T-cell lymphomas: reappraisal of a provisional entity in the 2016 WHO classification of cutaneous lymphomas. Modern Pathology : An Official Journal Of The United States And Canadian Academy Of Pathology, Inc 2017, 30: 761-772. PMID: 28128277, PMCID: PMC5413429, DOI: 10.1038/modpathol.2016.240.
  • Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Immunotherapy.Shi VJ, Rodic N, Gettinger S, Leventhal JS, Neckman JP, Girardi M, Bosenberg M, Choi JN. Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Immunotherapy. JAMA Dermatology 2016, 152: 1128-1136. PMID: 27411054, PMCID: PMC6108080, DOI: 10.1001/jamadermatol.2016.2226.
  • Diverse cutaneous manifestations of Erdheim-Chester disease in a woman with a history of Langerhans cell histiocytosis.Neckman JP, Kim J, Mathur M, Myung P, Girardi M. Diverse cutaneous manifestations of Erdheim-Chester disease in a woman with a history of Langerhans cell histiocytosis. JAAD Case Reports 2016, 2: 128-31. PMID: 27051852, PMCID: PMC4810280, DOI: 10.1016/j.jdcr.2015.10.010.
  • Cutaneous T-cell lymphoma (CTCL): Current practices in blood assessment and the utility of T-cell receptor (TCR)-Vβ chain restriction.Gibson JF, Huang J, Liu KJ, Carlson KR, Foss F, Choi J, Edelson R, Hussong JW, Mohl R, Hill S, Girardi M. Cutaneous T-cell lymphoma (CTCL): Current practices in blood assessment and the utility of T-cell receptor (TCR)-Vβ chain restriction. Journal Of The American Academy Of Dermatology 2016, 74: 870-7. PMID: 26874819, PMCID: PMC4835257, DOI: 10.1016/j.jaad.2015.12.018.
  • Induction of anti-tumor CD8 T cell responses by experimental ECP-induced human dendritic antigen presenting cells.Kibbi N, Sobolev O, Girardi M, Edelson RL. Induction of anti-tumor CD8 T cell responses by experimental ECP-induced human dendritic antigen presenting cells. Transfusion And Apheresis Science : Official Journal Of The World Apheresis Association : Official Journal Of The European Society For Haemapheresis 2016, 55: 146-52. PMID: 27317354, DOI: 10.1016/j.transci.2016.06.001.
  • Mechanisms of chemical cooperative carcinogenesis by epidermal Langerhans cells.Lewis JM, Bürgler CD, Fraser JA, Liao H, Golubets K, Kucher CL, Zhao PY, Filler RB, Tigelaar RE, Girardi M. Mechanisms of chemical cooperative carcinogenesis by epidermal Langerhans cells. The Journal Of Investigative Dermatology 2015, 135: 1405-1414. PMID: 25233073, PMCID: PMC4364923, DOI: 10.1038/jid.2014.411.
  • A sunblock based on bioadhesive nanoparticles.Deng Y, Ediriwickrema A, Yang F, Lewis J, Girardi M, Saltzman WM. A sunblock based on bioadhesive nanoparticles. Nature Materials 2015, 14: 1278-85. PMID: 26413985, PMCID: PMC4654636, DOI: 10.1038/nmat4422.
  • CD4 + primary cutaneous small/medium-sized pleomorphic T-cell lymphoma: a retrospective case series and review of literature.James E, Sokhn JG, Gibson JF, Carlson K, Subtil A, Girardi M, Wilson LD, Foss F. CD4 + primary cutaneous small/medium-sized pleomorphic T-cell lymphoma: a retrospective case series and review of literature. Leukemia & Lymphoma 2015, 56: 951-7. PMID: 24996443, DOI: 10.3109/10428194.2014.938331.
  • The difficult--and often delayed--diagnosis of CTCL.Weed J, Girardi M. The difficult--and often delayed--diagnosis of CTCL. Science Translational Medicine 2015, 7: 308fs41. PMID: 26446952, DOI: 10.1126/scitranslmed.aad2518.
  • Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model.Scarisbrick JJ, Prince HM, Vermeer MH, Quaglino P, Horwitz S, Porcu P, Stadler R, Wood GS, Beylot-Barry M, Pham-Ledard A, Foss F, Girardi M, Bagot M, Michel L, Battistella M, Guitart J, Kuzel TM, Martinez-Escala ME, Estrach T, Papadavid E, Antoniou C, Rigopoulos D, Nikolaou V, Sugaya M, Miyagaki T, Gniadecki R, Sanches JA, Cury-Martins J, Miyashiro D, Servitje O, Muniesa C, Berti E, Onida F, Corti L, Hodak E, Amitay-Laish I, Ortiz-Romero PL, Rodríguez-Peralto JL, Knobler R, Porkert S, Bauer W, Pimpinelli N, Grandi V, Cowan R, Rook A, Kim E, Pileri A, Patrizi A, Pujol RM, Wong H, Tyler K, Stranzenbach R, Querfeld C, Fava P, Maule M, Willemze R, Evison F, Morris S, Twigger R, Talpur R, Kim J, Ognibene G, Li S, Tavallaee M, Hoppe RT, Duvic M, Whittaker SJ, Kim YH. Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2015, 33: 3766-73. PMID: 26438120, PMCID: PMC4979132, DOI: 10.1200/JCO.2015.61.7142.
  • Hematopoietic stem cell transplantation for primary cutaneous γδ T-cell lymphoma and refractory subcutaneous panniculitis-like T-cell lymphoma.Gibson JF, Alpdogan O, Subtil A, Girardi M, Wilson LD, Roberts K, Foss F. Hematopoietic stem cell transplantation for primary cutaneous γδ T-cell lymphoma and refractory subcutaneous panniculitis-like T-cell lymphoma. Journal Of The American Academy Of Dermatology 2015, 72: 1010-5.e5. PMID: 25981001, DOI: 10.1016/j.jaad.2015.01.003.
  • Langerhans Cells Facilitate UVB-Induced Epidermal Carcinogenesis.Lewis JM, Bürgler CD, Freudzon M, Golubets K, Gibson JF, Filler RB, Girardi M. Langerhans Cells Facilitate UVB-Induced Epidermal Carcinogenesis. The Journal Of Investigative Dermatology 2015, 135: 2824-2833. PMID: 26053049, PMCID: PMC4640962, DOI: 10.1038/jid.2015.207.
  • Genomic landscape of cutaneous T cell lymphoma.Choi J, Goh G, Walradt T, Hong BS, Bunick CG, Chen K, Bjornson RD, Maman Y, Wang T, Tordoff J, Carlson K, Overton JD, Liu KJ, Lewis JM, Devine L, Barbarotta L, Foss FM, Subtil A, Vonderheid EC, Edelson RL, Schatz DG, Boggon TJ, Girardi M, Lifton RP. Genomic landscape of cutaneous T cell lymphoma. Nature Genetics 2015, 47: 1011-9. PMID: 26192916, PMCID: PMC4552614, DOI: 10.1038/ng.3356.
  • Induction of monocyte-to-dendritic cell maturation by extracorporeal photochemotherapy: initiation via direct platelet signaling.Durazzo TS, Tigelaar RE, Filler R, Hayday A, Girardi M, Edelson RL. Induction of monocyte-to-dendritic cell maturation by extracorporeal photochemotherapy: initiation via direct platelet signaling. Transfusion And Apheresis Science : Official Journal Of The World Apheresis Association : Official Journal Of The European Society For Haemapheresis 2014, 50: 370-8. PMID: 24360371, PMCID: PMC4167725, DOI: 10.1016/j.transci.2013.11.008.
  • Integrin-driven monocyte to dendritic cell conversion in modified extracorporeal photochemotherapy.Gonzalez AL, Berger CL, Remington J, Girardi M, Tigelaar RE, Edelson RL. Integrin-driven monocyte to dendritic cell conversion in modified extracorporeal photochemotherapy. Clinical And Experimental Immunology 2014, 175: 449-57. PMID: 24188174, PMCID: PMC3927905, DOI: 10.1111/cei.12231.
  • Posttraumatic eczema: a manifestation of the atopic diathesis?Greiling TM, Galan A, Girardi M, Watsky KL. Posttraumatic eczema: a manifestation of the atopic diathesis? Dermatitis : Contact, Atopic, Occupational, Drug 2014, 25: 376-7. PMID: 25384225, PMCID: PMC4865885, DOI: 10.1097/DER.0000000000000088.
  • IL-9 regulates allergen-specific Th1 responses in allergic contact dermatitis.Liu J, Harberts E, Tammaro A, Girardi N, Filler RB, Fishelevich R, Temann A, Licona-Limón P, Girardi M, Flavell RA, Gaspari AA. IL-9 regulates allergen-specific Th1 responses in allergic contact dermatitis. The Journal Of Investigative Dermatology 2014, 134: 1903-1911. PMID: 24487305, PMCID: PMC4303591, DOI: 10.1038/jid.2014.61.
  • Case experience of 308-nm excimer laser therapy compatibility with PUVA and oral bexarotene for the treatment of cutaneous lesions in mycosis fungoides.Huang J, Cowper S, Moss J, Girardi M. Case experience of 308-nm excimer laser therapy compatibility with PUVA and oral bexarotene for the treatment of cutaneous lesions in mycosis fungoides. Journal Of Drugs In Dermatology : JDD 2013, 12: 487-9. PMID: 23652902.
  • Acute toxicity and risk of infection during total skin electron beam therapy for mycosis fungoides.Lloyd S, Chen Z, Foss FM, Girardi M, Wilson LD. Acute toxicity and risk of infection during total skin electron beam therapy for mycosis fungoides. Journal Of The American Academy Of Dermatology 2013, 69: 537-43. PMID: 23849563, DOI: 10.1016/j.jaad.2013.04.063.
  • Periorificial dermatitis and erosive inguinal plaques in a 57-year-old woman. Acquired zinc deficiency acrodermatitis enteropathica (ADE).Lott JP, Reeve J, Ko C, Girardi M. Periorificial dermatitis and erosive inguinal plaques in a 57-year-old woman. Acquired zinc deficiency acrodermatitis enteropathica (ADE). JAMA Dermatology 2013, 149: 357-63. PMID: 23552816, DOI: 10.1001/archderm.149.3.358-b.
  • Development of a plaque infiltrated with large CD30+ T cells over a silicone-containing device in a patient with history of Sézary syndrome.Engberg AK, Bunick CG, Subtil A, Ko CJ, Girardi M. Development of a plaque infiltrated with large CD30+ T cells over a silicone-containing device in a patient with history of Sézary syndrome. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2013, 31: e87-9. PMID: 23182990, PMCID: PMC4855504, DOI: 10.1200/JCO.2012.42.9241.
  • “Extracorporeal Photochemotherapy” in Comprehensive Dermatologic Drug TherapyGirardi M, Choi J, Heald PW. “Extracorporeal Photochemotherapy” in Comprehensive Dermatologic Drug Therapy, S. Wolvertin, (ed), 3rd Ed. W.B. Saunders, Philadelphia, 2012.
  • Characterization of the DNA copy-number genome in the blood of cutaneous T-cell lymphoma patients.Lin WM, Lewis JM, Filler RB, Modi BG, Carlson KR, Reddy S, Thornberg A, Saksena G, Umlauf S, Oberholzer PA, Karpova M, Getz G, Mane S, Garraway LA, Dummer R, Berger CL, Edelson RL, Girardi M. Characterization of the DNA copy-number genome in the blood of cutaneous T-cell lymphoma patients. The Journal Of Investigative Dermatology 2012, 132: 188-97. PMID: 21881587, PMCID: PMC3841973, DOI: 10.1038/jid.2011.254.
  • Mycosis fungoides exhibiting features of a dermatofibroma: a case report and review of the literature.Morcos SM, Girardi M, Subtil A, Wilson LD, Cowper SE. Mycosis fungoides exhibiting features of a dermatofibroma: a case report and review of the literature. Journal Of Cutaneous Pathology 2012, 39: 40-6. PMID: 22059953, DOI: 10.1111/j.1600-0560.2011.01804.x.
  • Dialogues in dermatology: Highlights from 2011.Lott JP, Robinson D, Warren C, Klein R, Craiglow B, Girardi M. Dialogues in dermatology: Highlights from 2011. Journal Of The American Academy Of Dermatology 2012, 66: 153-6. PMID: 22177634, DOI: 10.1016/j.jaad.2011.10.018.
  • Langerhans cells facilitate epithelial DNA damage and squamous cell carcinoma.Modi BG, Neustadter J, Binda E, Lewis J, Filler RB, Roberts SJ, Kwong BY, Reddy S, Overton JD, Galan A, Tigelaar R, Cai L, Fu P, Shlomchik M, Kaplan DH, Hayday A, Girardi M. Langerhans cells facilitate epithelial DNA damage and squamous cell carcinoma. Science (New York, N.Y.) 2012, 335: 104-8. PMID: 22223807, PMCID: PMC3753811, DOI: 10.1126/science.1211600.
  • High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade.Kiessling MK, Oberholzer PA, Mondal C, Karpova MB, Zipser MC, Lin WM, Girardi M, Macconaill LE, Kehoe SM, Hatton C, French LE, Garraway LA, Polier G, Süss D, Klemke CD, Krammer PH, Gülow K, Dummer R. High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade. Blood 2011, 117: 2433-40. PMID: 21209378, PMCID: PMC3952811, DOI: 10.1182/blood-2010-09-305128.
  • Nephrogenic systemic fibrosis: clinicopathological definition and workup recommendations.Girardi M, Kay J, Elston DM, Leboit PE, Abu-Alfa A, Cowper SE. Nephrogenic systemic fibrosis: clinicopathological definition and workup recommendations. Journal Of The American Academy Of Dermatology 2011, 65: 1095-1106.e7. PMID: 21724294, DOI: 10.1016/j.jaad.2010.08.041.
  • Practice gaps. The hard task of measuring cutaneous fibrosis: comment on "14-MHz ultrasonography as an outcome measure in morphea (localized scleroderma)".Lott JP, Girardi M. Practice gaps. The hard task of measuring cutaneous fibrosis: comment on "14-MHz ultrasonography as an outcome measure in morphea (localized scleroderma)". Archives Of Dermatology 2011, 147: 1115-6. PMID: 21931058, DOI: 10.1001/archdermatol.2011.244.
  • Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer.Olsen EA, Whittaker S, Kim YH, Duvic M, Prince HM, Lessin SR, Wood GS, Willemze R, Demierre MF, Pimpinelli N, Bernengo MG, Ortiz-Romero PL, Bagot M, Estrach T, Guitart J, Knobler R, Sanches JA, Iwatsuki K, Sugaya M, Dummer R, Pittelkow M, Hoppe R, Parker S, Geskin L, Pinter-Brown L, Girardi M, Burg G, Ranki A, Vermeer M, Horwitz S, Heald P, Rosen S, Cerroni L, Dreno B, Vonderheid EC. Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2011, 29: 2598-607. PMID: 21576639, PMCID: PMC3422534, DOI: 10.1200/JCO.2010.32.0630.
  • Renal transplantation for nephrogenic systemic fibrosis: a case report and review of the literature.Cuffy MC, Singh M, Formica R, Simmons E, Abu Alfa AK, Carlson K, Girardi M, Cowper SE, Kulkarni S. Renal transplantation for nephrogenic systemic fibrosis: a case report and review of the literature. Nephrology, Dialysis, Transplantation : Official Publication Of The European Dialysis And Transplant Association - European Renal Association 2011, 26: 1099-101. PMID: 21079195, DOI: 10.1093/ndt/gfq693.
  • Molecular analysis of tumor-promoting CD8+ T cells in two-stage cutaneous chemical carcinogenesis.Kwong BY, Roberts SJ, Silberzahn T, Filler RB, Neustadter JH, Galan A, Reddy S, Lin WM, Ellis PD, Langford CF, Hayday AC, Girardi M. Molecular analysis of tumor-promoting CD8+ T cells in two-stage cutaneous chemical carcinogenesis. The Journal Of Investigative Dermatology 2010, 130: 1726-36. PMID: 19924136, PMCID: PMC2920801, DOI: 10.1038/jid.2009.362.
  • The contribution of Langerhans cells to cutaneous malignancy.Lewis J, Filler R, Smith DA, Golubets K, Girardi M. The contribution of Langerhans cells to cutaneous malignancy. Trends In Immunology 2010, 31: 460-6. PMID: 21071271, PMCID: PMC3753793, DOI: 10.1016/j.it.2010.10.001.
  • Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma.Kim YH, Girardi M, Duvic M, Kuzel T, Link BK, Pinter-Brown L, Rook AH. Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma. Journal Of The American Academy Of Dermatology 2010, 63: 975-83. PMID: 20888065, DOI: 10.1016/j.jaad.2009.12.052.
  • A transient epidermolysis bullosa simplex-like phenotype associated with bexarotene treatment in a G138E KRT5 heterozygote.Trufant JW, Kreizenbeck GM, Carlson KR, Muthusamy V, Girardi M, Bosenberg MW. A transient epidermolysis bullosa simplex-like phenotype associated with bexarotene treatment in a G138E KRT5 heterozygote. Journal Of Cutaneous Pathology 2010, 37: 1155-60. PMID: 20849457, DOI: 10.1111/j.1600-0560.2010.01557.x.
  • More or less: copy number alterations in mycosis fungoides.Lin WM, Girardi M. More or less: copy number alterations in mycosis fungoides. The Journal Of Investigative Dermatology 2010, 130: 926-8. PMID: 20231832, DOI: 10.1038/jid.2009.370.
  • Rapid generation of maturationally synchronized human dendritic cells: contribution to the clinical efficacy of extracorporeal photochemotherapy.Berger C, Hoffmann K, Vasquez JG, Mane S, Lewis J, Filler R, Lin A, Zhao H, Durazzo T, Baird A, Lin W, Foss F, Christensen I, Girardi M, Tigelaar R, Edelson R. Rapid generation of maturationally synchronized human dendritic cells: contribution to the clinical efficacy of extracorporeal photochemotherapy. Blood 2010, 116: 4838-47. PMID: 20720185, PMCID: PMC3321745, DOI: 10.1182/blood-2009-11-256040.
  • Primary cutaneous aspergillosis in an immunocompetent patient: successful treatment with oral voriconazole.Craiglow B, Hinds G, Antaya R, Girardi M. Primary cutaneous aspergillosis in an immunocompetent patient: successful treatment with oral voriconazole. Pediatric Dermatology 2009, 26: 493-5. PMID: 19689543, DOI: 10.1111/j.1525-1470.2009.00971.x.
  • Extracorporeal photochemotherapy for generalized deep morphea.Neustadter JH, Samarin F, Carlson KR, Girardi M. Extracorporeal photochemotherapy for generalized deep morphea. Archives Of Dermatology 2009, 145: 127-30. PMID: 19221256, PMCID: PMC4075155, DOI: 10.1001/archdermatol.2008.547.
  • CD27 is a thymic determinant of the balance between interferon-gamma- and interleukin 17-producing gammadelta T cell subsets.Ribot JC, deBarros A, Pang DJ, Neves JF, Peperzak V, Roberts SJ, Girardi M, Borst J, Hayday AC, Pennington DJ, Silva-Santos B. CD27 is a thymic determinant of the balance between interferon-gamma- and interleukin 17-producing gammadelta T cell subsets. Nature Immunology 2009, 10: 427-36. PMID: 19270712, PMCID: PMC4167721, DOI: 10.1038/ni.1717.
  • Nephrogenic systemic fibrosis: a dermatologist's perspective.Girardi M. Nephrogenic systemic fibrosis: a dermatologist's perspective. Journal Of The American College Of Radiology : JACR 2008, 5: 40-4. PMID: 18180008, DOI: 10.1016/j.jacr.2007.08.017.
  • FDG-PET/CT in the evaluation of cutaneous T-cell lymphoma.Kuo PH, McClennan BL, Carlson K, Wilson LD, Edelson RL, Heald PW, Girardi M. FDG-PET/CT in the evaluation of cutaneous T-cell lymphoma. Molecular Imaging And Biology : MIB : The Official Publication Of The Academy Of Molecular Imaging 2008, 10: 74-81. PMID: 18196347, DOI: 10.1007/s11307-007-0127-y.
  • Clinical and histological findings in nephrogenic systemic fibrosis.Cowper SE, Rabach M, Girardi M. Clinical and histological findings in nephrogenic systemic fibrosis. European Journal Of Radiology 2008, 66: 191-9. PMID: 18325705, DOI: 10.1016/j.ejrad.2008.01.016.
  • Skint1, the prototype of a newly identified immunoglobulin superfamily gene cluster, positively selects epidermal gammadelta T cells.Boyden LM, Lewis JM, Barbee SD, Bas A, Girardi M, Hayday AC, Tigelaar RE, Lifton RP. Skint1, the prototype of a newly identified immunoglobulin superfamily gene cluster, positively selects epidermal gammadelta T cells. Nature Genetics 2008, 40: 656-62. PMID: 18408721, PMCID: PMC4167720, DOI: 10.1038/ng.108.
  • Scleroderma-like illness as a presenting feature of multiple myeloma and amyloidosis.Reyes CM, Rudinskaya A, Kloss R, Girardi M, Lazova R. Scleroderma-like illness as a presenting feature of multiple myeloma and amyloidosis. Journal Of Clinical Rheumatology : Practical Reports On Rheumatic & Musculoskeletal Diseases 2008, 14: 161-5. PMID: 18525436, DOI: 10.1097/RHU.0b013e3181775a15.
  • Pemphigoid vegetans: a case report and review of the literature.Kim J, Chavel S, Girardi M, McNiff JM. Pemphigoid vegetans: a case report and review of the literature. Journal Of Cutaneous Pathology 2008, 35: 1144-47. PMID: 18988318, DOI: 10.1111/j.1600-0560.2008.01016.x.
  • FDG-PET/CT for the evaluation of response to therapy of cutaneous T-cell lymphoma to vorinostat (suberoylanilide hydroxamic acid, SAHA) in a phase II trial.Kuo PH, Carlson KR, Christensen I, Girardi M, Heald PW. FDG-PET/CT for the evaluation of response to therapy of cutaneous T-cell lymphoma to vorinostat (suberoylanilide hydroxamic acid, SAHA) in a phase II trial. Molecular Imaging And Biology : MIB : The Official Publication Of The Academy Of Molecular Imaging 2008, 10: 306-14. PMID: 18665425, DOI: 10.1007/s11307-008-0161-4.
  • Acute upregulation of an NKG2D ligand promotes rapid reorganization of a local immune compartment with pleiotropic effects on carcinogenesis.Strid J, Roberts SJ, Filler RB, Lewis JM, Kwong BY, Schpero W, Kaplan DH, Hayday AC, Girardi M. Acute upregulation of an NKG2D ligand promotes rapid reorganization of a local immune compartment with pleiotropic effects on carcinogenesis. Nature Immunology 2008, 9: 146-54. PMID: 18176566, DOI: 10.1038/ni1556.
  • Cutaneous T cell lymphoma: translating immunobiology into therapeutic opportunities.Berger CL, Heald P, Girardi M, Edelson RL. Cutaneous T cell lymphoma: translating immunobiology into therapeutic opportunities. Giornale Italiano Di Dermatologia E Venereologia : Organo Ufficiale, Societa` Italiana Di Dermatologia E Sifilografia 2008, 143: 43-54. PMID: 18833050.
  • Cutaneous two-stage chemical carcinogenesis.Filler RB, Roberts SJ, Girardi M. Cutaneous two-stage chemical carcinogenesis. CSH Protocols 2007, 2007: pdb.prot4837. PMID: 21357170, DOI: 10.1101/pdb.prot4837.
  • Cutaneous perspectives on adaptive immunity.Girardi M. Cutaneous perspectives on adaptive immunity. Clinical Reviews In Allergy & Immunology 2007, 33: 4-14. PMID: 18094943, DOI: 10.1007/s12016-007-0040-9.
  • Promotion of Hras-induced squamous carcinomas by a polymorphic variant of the Patched gene in FVB mice.Wakabayashi Y, Mao JH, Brown K, Girardi M, Balmain A. Promotion of Hras-induced squamous carcinomas by a polymorphic variant of the Patched gene in FVB mice. Nature 2007, 445: 761-5. PMID: 17230190, DOI: 10.1038/nature05489.
  • Characterizing tumor-promoting T cells in chemically induced cutaneous carcinogenesis.Roberts SJ, Ng BY, Filler RB, Lewis J, Glusac EJ, Hayday AC, Tigelaar RE, Girardi M. Characterizing tumor-promoting T cells in chemically induced cutaneous carcinogenesis. Proceedings Of The National Academy Of Sciences Of The United States Of America 2007, 104: 6770-5. PMID: 17412837, PMCID: PMC1871860, DOI: 10.1073/pnas.0604982104.
  • A systematic review of the safety of topical therapies for atopic dermatitis.Callen J, Chamlin S, Eichenfield LF, Ellis C, Girardi M, Goldfarb M, Hanifin J, Lee P, Margolis D, Paller AS, Piacquadio D, Peterson W, Kaulback K, Fennerty M, Wintroub BU. A systematic review of the safety of topical therapies for atopic dermatitis. The British Journal Of Dermatology 2007, 156: 203-21. PMID: 17223859, DOI: 10.1111/j.1365-2133.2006.07538.x.
  • Selection of the cutaneous intraepithelial gammadelta+ T cell repertoire by a thymic stromal determinant.Lewis JM, Girardi M, Roberts SJ, Barbee SD, Hayday AC, Tigelaar RE. Selection of the cutaneous intraepithelial gammadelta+ T cell repertoire by a thymic stromal determinant. Nature Immunology 2006, 7: 843-50. PMID: 16829962, DOI: 10.1038/ni1363.
  • The therapeutic potential of extracorporeal photopheresis.Girardi M. The therapeutic potential of extracorporeal photopheresis. Clinical Advances In Hematology & Oncology : H&O 2006, 4: 349-50. PMID: 16728944.
  • Immunosurveillance and immunoregulation by gammadelta T cells.Girardi M. Immunosurveillance and immunoregulation by gammadelta T cells. The Journal Of Investigative Dermatology 2006, 126: 25-31. PMID: 16417214, DOI: 10.1038/sj.jid.5700003.
  • Transimmunization for cutaneous T cell lymphoma: a Phase I study.Girardi M, Berger CL, Wilson LD, Christensen IR, Thompson KR, Glusac EJ, Edelson RL. Transimmunization for cutaneous T cell lymphoma: a Phase I study. Leukemia & Lymphoma 2006, 47: 1495-503. PMID: 16966259, DOI: 10.1080/10428190600581419.
  • Environmentally responsive and reversible regulation of epidermal barrier function by gammadelta T cells.Girardi M, Lewis JM, Filler RB, Hayday AC, Tigelaar RE. Environmentally responsive and reversible regulation of epidermal barrier function by gammadelta T cells. The Journal Of Investigative Dermatology 2006, 126: 808-14. PMID: 16439970, DOI: 10.1038/sj.jid.5700120.
  • Cross-comparison of patch test and lymphocyte proliferation responses in patients with a history of acute generalized exanthematous pustulosis.Girardi M, Duncan KO, Tigelaar RE, Imaeda S, Watsky KL, McNiff JM. Cross-comparison of patch test and lymphocyte proliferation responses in patients with a history of acute generalized exanthematous pustulosis. The American Journal Of Dermatopathology 2005, 27: 343-6. PMID: 16121058, DOI: 10.1097/01.dad.0000160982.75176.6c.
  • Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance.Oppenheim DE, Roberts SJ, Clarke SL, Filler R, Lewis JM, Tigelaar RE, Girardi M, Hayday AC. Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance. Nature Immunology 2005, 6: 928-37. PMID: 16116470, DOI: 10.1038/ni1239.
  • Immunosurveillance by gammadelta T cells: focus on the murine system.Girardi M, Hayday AC. Immunosurveillance by gammadelta T cells: focus on the murine system. Chemical Immunology And Allergy 2005, 86: 136-150. PMID: 15976492, DOI: 10.1159/000086658.
  • Characterizing the protective component of the alphabeta T cell response to transplantable squamous cell carcinoma.Girardi M, Oppenheim D, Glusac EJ, Filler R, Balmain A, Tigelaar RE, Hayday AC. Characterizing the protective component of the alphabeta T cell response to transplantable squamous cell carcinoma. The Journal Of Investigative Dermatology 2004, 122: 699-706. PMID: 15086556, DOI: 10.1111/j.0022-202X.2004.22342.x.
  • The pathogenesis of mycosis fungoides.Girardi M, Heald PW, Wilson LD. The pathogenesis of mycosis fungoides. The New England Journal Of Medicine 2004, 350: 1978-88. PMID: 15128898, DOI: 10.1056/NEJMra032810.
  • Cutaneous biology of gammadelta T cells.Girardi M. Cutaneous biology of gammadelta T cells. Advances In Dermatology 2004, 20: 203-15. PMID: 15544201.
  • Advances in understanding the immunobiology and immunotherapy of cutaneous T-cell lymphoma.Berger CL, Mariwalla K, Girardi M, Edelson RL. Advances in understanding the immunobiology and immunotherapy of cutaneous T-cell lymphoma. Advances In Dermatology 2004, 20: 217-35. PMID: 15544202.
  • Gamma delta T cells provide an early source of interferon gamma in tumor immunity.Gao Y, Yang W, Pan M, Scully E, Girardi M, Augenlicht LH, Craft J, Yin Z. Gamma delta T cells provide an early source of interferon gamma in tumor immunity. The Journal Of Experimental Medicine 2003, 198: 433-42. PMID: 12900519, PMCID: PMC2194096, DOI: 10.1084/jem.20030584.
  • Anti-inflammatory effects in the skin of thymosin-beta4 splice-variants.Girardi M, Sherling MA, Filler RB, Shires J, Theodoridis E, Hayday AC, Tigelaar RE. Anti-inflammatory effects in the skin of thymosin-beta4 splice-variants. Immunology 2003, 109: 1-7. PMID: 12709011, PMCID: PMC1782938, DOI: 10.1046/j.1365-2567.2003.01616.x.
  • The distinct contributions of murine T cell receptor (TCR)gammadelta+ and TCRalphabeta+ T cells to different stages of chemically induced skin cancer.Girardi M, Glusac E, Filler RB, Roberts SJ, Propperova I, Lewis J, Tigelaar RE, Hayday AC. The distinct contributions of murine T cell receptor (TCR)gammadelta+ and TCRalphabeta+ T cells to different stages of chemically induced skin cancer. The Journal Of Experimental Medicine 2003, 198: 747-55. PMID: 12953094, PMCID: PMC2194182, DOI: 10.1084/jem.20021282.
  • Selective immmunotherapy through extracorporeal photochemotherapy: yesterday, today, and tomorrow.Girardi M, Knobler R, Edelson R. Selective immmunotherapy through extracorporeal photochemotherapy: yesterday, today, and tomorrow. Hematology/oncology Clinics Of North America 2003, 17: 1391-403. PMID: 14710891, DOI: 10.1016/s0889-8588(03)00106-0.
  • Efficient tumor antigen loading of dendritic antigen presenting cells by transimmunization.Girardi M, Berger C, Hanlon D, Edelson RL. Efficient tumor antigen loading of dendritic antigen presenting cells by transimmunization. Technology In Cancer Research & Treatment 2002, 1: 65-9. PMID: 12614179, DOI: 10.1177/153303460200100109.
  • Resident skin-specific gammadelta T cells provide local, nonredundant regulation of cutaneous inflammation.Girardi M, Lewis J, Glusac E, Filler RB, Geng L, Hayday AC, Tigelaar RE. Resident skin-specific gammadelta T cells provide local, nonredundant regulation of cutaneous inflammation. The Journal Of Experimental Medicine 2002, 195: 855-67. PMID: 11927630, PMCID: PMC2193718, DOI: 10.1084/jem.20012000.
  • Transimmunization, a novel approach for tumor immunotherapy.Berger CL, Hanlon D, Kanada D, Girardi M, Edelson RL. Transimmunization, a novel approach for tumor immunotherapy. Transfusion And Apheresis Science : Official Journal Of The World Apheresis Association : Official Journal Of The European Society For Haemapheresis 2002, 26: 205-16. PMID: 12126207, DOI: 10.1016/s1473-0502(02)00014-9.
  • Transimmunization and the evolution of extracorporeal photochemotherapy.Girardi M, Schechner J, Glusac E, Berger C, Edelson R. Transimmunization and the evolution of extracorporeal photochemotherapy. Transfusion And Apheresis Science : Official Journal Of The World Apheresis Association : Official Journal Of The European Society For Haemapheresis 2002, 26: 181-90. PMID: 12126204, DOI: 10.1016/s1473-0502(02)00011-3.
  • The clonotypic T cell receptor is a source of tumor-associated antigens in cutaneous T cell lymphoma.Berger CL, Longley J, Hanlon D, Girardi M, Edelson R. The clonotypic T cell receptor is a source of tumor-associated antigens in cutaneous T cell lymphoma. Annals Of The New York Academy Of Sciences 2001, 941: 106-22. PMID: 11594564, DOI: 10.1111/j.1749-6632.2001.tb03715.x.
  • Regulation of cutaneous malignancy by gammadelta T cells.Girardi M, Oppenheim DE, Steele CR, Lewis JM, Glusac E, Filler R, Hobby P, Sutton B, Tigelaar RE, Hayday AC. Regulation of cutaneous malignancy by gammadelta T cells. Science (New York, N.Y.) 2001, 294: 605-9. PMID: 11567106, DOI: 10.1126/science.1063916.
  • Extracorporeal photochemoimmunotherapy in cutaneous T cell lymphomas.Knobler R, Girardi M. Extracorporeal photochemoimmunotherapy in cutaneous T cell lymphomas. Annals Of The New York Academy Of Sciences 2001, 941: 123-38. PMID: 11594566, DOI: 10.1111/j.1749-6632.2001.tb03716.x.
  • Cutaneous T-cell lymphoma: pathogenesis and treatment.Girardi M, Edelson RL. Cutaneous T-cell lymphoma: pathogenesis and treatment. Oncology (Williston Park, N.Y.) 2000, 14: 1061-70; discussion 1070-4, 1076. PMID: 10929591.
  • Postirradiation morphea of the breast presentation of two cases and review of the literature.Schaffer JV, Carroll C, Dvoretsky I, Huether MJ, Girardi M. Postirradiation morphea of the breast presentation of two cases and review of the literature. Dermatology (Basel, Switzerland) 2000, 200: 67-71. PMID: 10681621, DOI: 10.1159/000018322.
  • Cutaneous T-cell lymphoma and cutaneous graft-versus-host disease. Two indications for photopheresis in dermatology.Girardi M, Heald PW. Cutaneous T-cell lymphoma and cutaneous graft-versus-host disease. Two indications for photopheresis in dermatology. Dermatologic Clinics 2000, 18: 417-23, viii. PMID: 10943537, DOI: 10.1016/s0733-8635(05)70190-x.
  • Extracorporeal photochemotherapy in human and murine graft-versus-host disease.Girardi M, McNiff JM, Heald PW. Extracorporeal photochemotherapy in human and murine graft-versus-host disease. Journal Of Dermatological Science 1999, 19: 106-13. PMID: 10098701, DOI: 10.1016/s0923-1811(98)00066-8.
  • Subcutaneous Fusarium foot abscess in a renal transplant patient.Girardi M, Glusac EJ, Imaeda S. Subcutaneous Fusarium foot abscess in a renal transplant patient. Cutis 1999, 63: 267-70. PMID: 10349541.
  • Familial multiple basaloid follicular hamartomas: A report of two affected sisters.Girardi M, Federman GL, McNiff JM. Familial multiple basaloid follicular hamartomas: A report of two affected sisters. Pediatric Dermatology 1999, 16: 281-4. PMID: 10469412, DOI: 10.1046/j.1525-1470.1999.00061.x.
  • Alpha beta and gamma delta T cells can share a late common precursor.Dudley EC, Girardi M, Owen MJ, Hayday AC. Alpha beta and gamma delta T cells can share a late common precursor. Current Biology : CB 1995, 5: 659-69. PMID: 7552177, DOI: 10.1016/s0960-9822(95)00131-x.
  • Specific suppression of lupus-like graft-versus-host disease using extracorporeal photochemical attenuation of effector lymphocytes.Girardi M, Herreid P, Tigelaar RE. Specific suppression of lupus-like graft-versus-host disease using extracorporeal photochemical attenuation of effector lymphocytes. The Journal Of Investigative Dermatology 1995, 104: 177-82. PMID: 7829872, DOI: 10.1111/1523-1747.ep12612741.
  • Primary Treatment Selection for Clinically Node-Negative Merkel Cell Carcinoma of the Head and Neck.Jacobs D, Olino K, Park HS, Clune J, Cheraghlou S, Girardi M, Burtness B, Kluger H, Judson BL. Primary Treatment Selection for Clinically Node-Negative Merkel Cell Carcinoma of the Head and Neck. Otolaryngology--head And Neck Surgery : Official Journal Of American Academy Of Otolaryngology-Head And Neck Surgery 2021, 164: 1214-1221. PMID: 33079010, DOI: 10.1177/0194599820967001.
  • Research Techniques Made Simple: Preclinical Development of Combination Antitumor Targeted Therapies in Dermatology.Yumeen S, Mirza FN, Lewis JM, Girardi M. Research Techniques Made Simple: Preclinical Development of Combination Antitumor Targeted Therapies in Dermatology. The Journal Of Investigative Dermatology 2020, 140: 2319-2325.e1. PMID: 33222758, DOI: 10.1016/j.jid.2020.09.020.
  • Nonsurgical treatment of skin cancer with local delivery of bioadhesive nanoparticles.Hu JK, Suh HW, Qureshi M, Lewis JM, Yaqoob S, Moscato ZM, Griff S, Lee AK, Yin ES, Saltzman WM, Girardi M. Nonsurgical treatment of skin cancer with local delivery of bioadhesive nanoparticles. Proceedings Of The National Academy Of Sciences Of The United States Of America 2021, 118 PMID: 33526595, PMCID: PMC7896333, DOI: 10.1073/pnas.2020575118.
  • B-cell lymphoma 2 inhibitor venetoclax treatment of a patient with cutaneous T-cell lymphoma.King ALO, Mirza FN, Lewis JM, Carlson KR, Huntington S, Foss FM, Girardi M. B-cell lymphoma 2 inhibitor venetoclax treatment of a patient with cutaneous T-cell lymphoma. JAAD Case Reports 2021, 8: 89-92. PMID: 33537387, PMCID: PMC7838714, DOI: 10.1016/j.jdcr.2020.12.025.
  • The PROVe Study: US Real-World Experience with Chlormethine/Mechlorethamine Gel in Combination with Other Therapies for Patients with Mycosis Fungoides Cutaneous T-Cell Lymphoma.Kim EJ, Guitart J, Querfeld C, Girardi M, Musiek A, Akilov OE, Angello JT, Bailey WL, Geskin LJ. The PROVe Study: US Real-World Experience with Chlormethine/Mechlorethamine Gel in Combination with Other Therapies for Patients with Mycosis Fungoides Cutaneous T-Cell Lymphoma. American Journal Of Clinical Dermatology 2021, 22: 407-414. PMID: 33656660, PMCID: PMC8068681, DOI: 10.1007/s40257-021-00591-x.
  • Association of Treatment Facility Characteristics With Overall Survival After Mohs Micrographic Surgery for T1a-T2a Invasive Melanoma.Cheraghlou S, Christensen SR, Leffell DJ, Girardi M. Association of Treatment Facility Characteristics With Overall Survival After Mohs Micrographic Surgery for T1a-T2a Invasive Melanoma. JAMA Dermatology 2021, 157: 531-539. PMID: 33787836, PMCID: PMC8014201, DOI: 10.1001/jamadermatol.2021.0023.
  • Necrotic papulonodules on the legs.Zhou A, Damsky W, Girardi M, Foss FM, Vesely MD. Necrotic papulonodules on the legs. JAAD Case Reports 2021, 11: 10-12. PMID: 33898676, PMCID: PMC8056172, DOI: 10.1016/j.jdcr.2021.03.012.
  • A machine-learning modified CART algorithm informs Merkel cell carcinoma prognosis.Cheraghlou S, Sadda P, Agogo GO, Girardi M. A machine-learning modified CART algorithm informs Merkel cell carcinoma prognosis. The Australasian Journal Of Dermatology 2021, 62: 323-330. PMID: 34028790, DOI: 10.1111/ajd.13624.
  • Uncovering the Potential of Phosphatidylinositol 3-Kinase Inhibitors in Cutaneous T-Cell Lymphoma: Insights from High-Throughput In Vitro Screenings.King ALO, Mirza FN, Lewis JM, Umlauf S, Surovtseva Y, Carlson KR, Foss FM, Girardi M. Uncovering the Potential of Phosphatidylinositol 3-Kinase Inhibitors in Cutaneous T-Cell Lymphoma: Insights from High-Throughput In Vitro Screenings. The Journal Of Investigative Dermatology 2022, 142: 254-257. PMID: 34293349, DOI: 10.1016/j.jid.2021.04.035.
  • Chronic UV radiation-induced RORγt+ IL-22-producing lymphoid cells are associated with mutant KC clonal expansion.Lewis JM, Monico PF, Mirza FN, Xu S, Yumeen S, Turban JL, Galan A, Girardi M. Chronic UV radiation-induced RORγt+ IL-22-producing lymphoid cells are associated with mutant KC clonal expansion. Proceedings Of The National Academy Of Sciences Of The United States Of America 2021, 118 PMID: 34504008, PMCID: PMC8449378, DOI: 10.1073/pnas.2016963118.
  • Primary Cutaneous Lymphoma: Recommendations for Clinical Trial Design and Staging Update from the ISCL, USCLC, and EORTC.Olsen EA, Whittaker S, Willemze R, Pinter-Brown L, Foss FM, Geskin LJ, Schwartz LH, Horwitz SM, Guitart J, Zic J, Kim YH, Wood GS, Duvic M, Ai WZ, Girardi M, Gru A, Guenova E, Hodak E, Hoppe RT, Kempf W, Kim EJ, Lechowicz MJ, Ortiz-Romero PL, Papadavid E, Quaglino P, Pittelkow MR, Prince HM, Sanches JA, Sugaya M, Vermeer MH, Zain J, Knobler R, Stadler R, Bagot M, Scarisbrick JJ. Primary Cutaneous Lymphoma: Recommendations for Clinical Trial Design and Staging Update from the ISCL, USCLC, and EORTC. Blood 2021 PMID: 34758074, DOI: 10.1182/blood.2021012057.
  • Sentinel Lymph Node Biopsy Positivity in Patients With Acral Lentiginous and Other Subtypes of Cutaneous Melanoma.Cheraghlou S, Ugwu N, Girardi M. Sentinel Lymph Node Biopsy Positivity in Patients With Acral Lentiginous and Other Subtypes of Cutaneous Melanoma. JAMA Dermatology 2022, 158: 51-58. PMID: 34878492, PMCID: PMC8655663, DOI: 10.1001/jamadermatol.2021.4812.
  • Malignant T Cell Activation by a Bacillus Species Isolated from Cutaneous T-Cell Lymphoma Lesions.Dehner CA, Ruff WE, Greiling T, Pereira MS, Redanz S, McNiff J, Girardi M, Kriegel MA. Malignant T Cell Activation by a Bacillus Species Isolated from Cutaneous T-Cell Lymphoma Lesions. JID Innovations 2022, 2: 100084. PMID: 35199089, PMCID: PMC8844718, DOI: 10.1016/j.xjidi.2021.100084.
  • Correction to: The PROVe Study: US Real-World Experience with Chlormethine/Mechlorethamine Gel in Combination with Other Therapies for Patients with Mycosis Fungoides Cutaneous T-Cell Lymphoma.Kim EJ, Guitart J, Querfeld C, Girardi M, Musiek A, Akilov OE, Angello JT, Bailey WL, Geskin LJ. Correction to: The PROVe Study: US Real-World Experience with Chlormethine/Mechlorethamine Gel in Combination with Other Therapies for Patients with Mycosis Fungoides Cutaneous T-Cell Lymphoma. American Journal Of Clinical Dermatology 2022, 23: 425. PMID: 35292936, DOI: 10.1007/s40257-022-00676-1.
  • Treatment at high-volume facilities is associated with improved overall survival for patients with cutaneous B-cell lymphoma.Cheraghlou S, Ugwu N, Girardi M. Treatment at high-volume facilities is associated with improved overall survival for patients with cutaneous B-cell lymphoma. Journal Of The American Academy Of Dermatology 2022 PMID: 35476920, DOI: 10.1016/j.jaad.2022.04.032.

Clinical Trials

Study Title
Molecular Markers of UV Exposure and Cancer Risk in Skin
Edit Profile